Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus ZL-1310 safety and tolerability trial in poorly differentiated neuroendocrine carcinoma
jRCT2031260627Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of obrixtamig, zocilurtatug pelitecan and atezolizumab in neuroendocrine carcinoma (NEC), small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities in Part 1, Adverse events leading to discontinuation or dose modification in Part 2 and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
obrixtamigzocilurtatug pelitecanatezolizumab
03
Conditions
neuroendocrine carcinoma (NEC)small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on jRCT2031260627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260627.